

1 **Methodological decisions influence the identification of potential core**  
2 **outcomes in studies related to pre-eclampsia: an analysis informing the**  
3 **development of recommendations for future core outcome set developers**  
4

5 James M. N. Duffy<sup>1,2</sup>, Martin Hirsch<sup>3</sup>, Sue Ziebland<sup>1</sup>, Richard J. McManus<sup>1</sup> and the  
6 International Collaboration to Harmonise Outcomes in Pre-eclampsia (iHOPE). \*steering  
7 committee listed at the end of manuscript.  
8

9 <sup>1</sup> Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United  
10 Kingdom.

11 <sup>2</sup> Institute for Women's Health, University College London, London, United Kingdom.

12 <sup>3</sup> University College Hospital, London, United Kingdom.  
13

14 **Correspondence to**

15 Dr James M. N. Duffy MBChB MRes BSc (Hons) PG HCL

16 Nuffield Department of Primary Care Health Sciences, University of Oxford

17 Oxford OX1 3BJ

18 United Kingdom

19 +447949066806 james.duffy@balliol.ox.ac.uk

20 @jamesmnduffy  
21

22 **Running title**

23 Developing a long list of potential core outcomes  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35

36 **Abstract**

37 **Objective**

38 To quantify the effect of different methodological decisions on the identification of potential  
39 core outcomes to inform the development of recommendations.

40 **Design**

41 Mixed methods study.

42 **Setting**

43 A core outcome set for pre-eclampsia was used as an exemplar.

44 **Sample**

45 A long list of potential core outcomes was developed by undertaking a systematic review of  
46 pre-eclampsia trials and performing a thematic analysis of in-depth patient interviews.

47 **Methods**

48 Specific methods used to generate long lists of potential core outcomes were evaluated,  
49 including limitations placed within the search strategy and varied approaches in the  
50 extraction of outcomes from published trial reports.

51 **Results**

52 Different methodological decisions had a substantial impact on the identification of potential  
53 core outcomes. Extracting outcomes from published pre-eclampsia trials was an effective  
54 way of identifying 48 maternal, eight fetal, 25 neonatal outcomes, and eight patient-reported  
55 outcomes. Limiting the extraction of outcomes to primary outcomes or outcomes commonly  
56 reported in pre-eclampsia trials reduced the number and diversity of potential core outcomes  
57 identified. Thematic analysis of in-depth patient interviews ensured an additional five patient  
58 reported outcomes and six outcomes related to future child health were identified.

59 **Conclusions**

60 Future core outcome set developers should use quantitative and qualitative methods when  
61 developing a long list of potential core outcomes.

62 **Funding**

63 National Institute for Health Research (DRF-2014-07-051)

64 **Keywords**

65 Core outcome sets; outcomes; pre-eclampsia; qualitative interviews; and systematic review.

66 **Tweetable abstract**

67 @OfficialNIHR research published in @BJOGtweets informs new recommendations for  
68 future @coreoutcomes developers

69

70

71

72

73

74

75

76

77

78

79

80

81

82

## 83 Introduction

84 Clinical research should ultimately improve patient care.<sup>1</sup> The ability of randomised  
85 controlled trials to inform clinical practice can be limited by several issues including the  
86 failure to consider the perspectives of patients when selecting outcomes, variations in  
87 outcome measures, and outcome reporting bias.<sup>2,3</sup> Problems with poor outcome selection,  
88 measurement, and reporting can be addressed by developing core outcome sets to  
89 standardise outcome selection, collection, and reporting across a specific disease area.<sup>4,5</sup>  
90 Over sixty core outcome sets are being developed across our speciality, including twin-twin  
91 transfusion syndrome, selective fetal growth restriction, and neonatal medicine.<sup>6-11</sup>

92

93 Core outcome sets are developed in three stages (Figure 1).<sup>12</sup> The first step is to develop a  
94 long list of potential core outcomes by undertaking a systematic review of published  
95 randomised controlled trials. A minority of core outcome set studies have also used  
96 qualitative methods, for example in-depth patient interviews.<sup>12</sup> The next step is to reduce the  
97 long list of potential core outcomes to a core outcome set using formal consensus methods,  
98 including the modified Delphi method. The final step is to determine how the core outcomes  
99 should be defined and measured.

100

101 As there is considerable uncertainty in core outcome set development methods, we  
102 undertook a systematic review of registered, ongoing, and completed core outcome sets  
103 relevant to women's and newborn health.<sup>13</sup> When delineating the specific methods used to  
104 generate a long list of potential core outcomes, there was considerable variation in the  
105 electronic bibliographical databases searched, differences in the limitations placed within the  
106 search strategy, including publication date, study size, and study design, and varied  
107 approaches in the extraction of outcomes from randomised trial reports. In addition to this  
108 heterogeneity in methodology, no examples were found of the use of qualitative research to  
109 capture patient views regarding potential core outcomes.

110 Understanding the most effective methods to use in this emerging field is important in order  
111 to reduce waste and unnecessary delays in the outcome set development process and to  
112 ensure a comprehensive approach is taken. The objective of this study was to quantify the  
113 effect of different methodological decisions on the identification of potential core outcomes to  
114 inform the development of specific recommendations for future core outcome set  
115 developers. A core outcome set for pre-eclampsia was used as an exemplar.<sup>14</sup>

116

## 117 **Methods**

118 The specific range of methods previously used to generate long lists of potential core  
119 outcomes were extracted from our systematic review of core outcome set development  
120 studies relevant to women's and newborn health.<sup>6</sup> These included differences in the  
121 limitations placed within the search strategy, including publication date, study size, and  
122 methodological quality, and varied approaches in the extraction of outcomes from  
123 randomised trial reports.

124

125 The impact of such methodological decisions was then explored using a systematic review  
126 of published pre-eclampsia trials and in-depth interviews, previously used for capturing  
127 potential core outcomes in pre-eclampsia. Detailed methods have been published elsewhere  
128 for each of the two underlying studies.<sup>15-18</sup>

129

130 Primary outcomes, secondary outcomes, along with study characteristics, were extracted  
131 from the systematic review.<sup>15, 18</sup> Primary outcomes were identified if they were explicitly  
132 stated or if an outcome was included in the study's power calculation.<sup>16</sup> Thematic analysis of  
133 thirty in-depth interviews with women with lived experience of pre-eclampsia was undertaken  
134 identified a further potential core outcome.<sup>17</sup> To facilitate comparisons, both sets of  
135 outcomes were organised within a standardised taxonomy (Figure 2).

136

137 Specific methodological decisions pertinent to the identification of potential core outcomes

138 were explored in this study, including:

139 ▪ No limitations placed within the search strategy, inclusion criteria, and all outcomes  
140 extracted from published trial reports.

141 ▪ Limitations placed within the search strategy, including:

142 1. Date limitation from 2007 onwards;

143 2. Larger trials reporting data from more than 100 participants; and

144 3. Trials assessed as higher methodological quality, defined as trials fulfilling the Jadad  
145 criteria.<sup>19</sup>

146 ▪ Different approaches in the extraction of outcomes from study reports, including

147 1. Primary outcomes; and

148 2. Commonly reported secondary outcomes, defined as a secondary outcome reported  
149 in three or more trials.

150 ▪ Outcomes identified by thematic analysis of in-depth interviews with women with lived  
151 experience of pre-eclampsia.

152

153 Descriptive tables formally quantified the effect of different methodological decisions on the  
154 identification of potential core outcomes (Figure 3).

155

156 Patients were not involved in the development of this research study. This is independent  
157 research arising from a doctoral fellowship (DRF-2014-07-051) supported by the National  
158 Institute for Health Research, awarded following external peer review. The funder had no  
159 role in the study design, data collection and analysis, decision to publish, or preparation of  
160 the manuscript.

161

162

163

## 164 **Results**

165 Seventy-nine pre-eclampsia trials reported 106 different outcomes and thematic analysis of  
166 30 in-depth interviews with women with lived experience of pre-eclampsia identified 71  
167 outcomes (Figure 2). Combining these resulted in one hundred and sixteen unique  
168 outcomes organised within a single standardised taxonomy. The impact of seven different  
169 methodological decisions were examined across seven outcome domains, including:

- 170 ▪ Mortality;
- 171 ▪ Maternal outcomes;
- 172 ▪ Patient reported outcomes;
- 173 ▪ Fetal outcomes;
- 174 ▪ Neonatal outcomes;
- 175 ▪ Childhood outcomes; and
- 176 ▪ Resource utilisation.

177

### 178 **Maternal, fetal, neonatal, and childhood mortality**

179 Different methodological decisions had no impact on the identification of maternal, fetal, or  
180 neonatal mortality as potential core outcomes (Figure S1). When only primary outcomes  
181 were extracted, neonatal and childhood mortality would not have been identified as a  
182 potential core outcome.

183

### 184 **Maternal outcomes**

185 The methodology used made a substantial difference in the number and diversity of  
186 maternal outcomes identified (Figure S2). Considering the results of the systematic review,  
187 when no limitations were placed within the search strategy, inclusion criteria, or outcome  
188 extraction, 48 maternal outcomes were identified. Limiting the search strategy reduced this  
189 to between 15 and 44 outcomes depending on the decision made. Important domains were  
190 not captured by some strategies, especially when the search was limited to primary

191 outcomes (gastrointestinal and neurological morbidity). Thematic analysis of in-depth patient  
192 interviews identified 24 maternal outcomes, a single domain, cardiovascular morbidity, was  
193 not represented.

194

#### 195 **Patient reported outcome**

196 Patient reported outcome assesses the patients' views of their health states, perceived level of  
197 impairment, disability, and health-related quality of life.<sup>20</sup> Considering the results of the  
198 systematic review, when no limitations were placed within the search strategy, inclusion  
199 criteria, or outcome extraction, five patient-reported outcomes were identified (Figure S3).  
200 Limiting the search strategy to larger and higher methodological quality trials did not reduce  
201 the number of patient-reported outcomes identified. Thematic analysis of in-depth patient  
202 interviews identified five additional patient reported outcomes.

203

#### 204 **Fetal outcomes**

205 Different methodological decisions resulted in differences in the number of fetal outcomes  
206 being identified (Figure S4). Considering the results of the systematic review, when no  
207 limitations were placed within the search strategy, inclusion criteria, or outcome extraction,  
208 eight fetal outcomes were identified. Limiting the search strategy reduced this to seven  
209 outcomes. When only primary outcomes were extracted from trial reports only three fetal  
210 outcomes were identified. Thematic analysis of in-depth patient interviews eclampsia  
211 identified six fetal outcomes.

212

#### 213 **Neonatal outcomes**

214 The methodology used made a substantial difference in the number and diversity of neonatal  
215 outcomes identified (Figure 4). Considering the results of the systematic review, when no  
216 limitations were placed within the search strategy, inclusion criteria, or outcome extraction,  
217 25 neonatal outcomes were identified. Limiting the search strategy reduced this to between  
218 19 and 25 outcomes depending on the decision made. Important domains were not captured



219 by some strategies, especially when the search was limited to primary outcomes, including  
220 neurological morbidity, gastrointestinal morbidity, and infectious morbidity. Thematic analysis  
221 of in-depth patient interviews identified 14 neonatal outcomes, three domains, neurological,  
222 cardiovascular, and haematological morbidity, was not represented.

223

#### 224 **Childhood outcomes**

225 The same six neurodevelopmental outcomes were identified when: (1) no limitations were  
226 placed within the search strategy, inclusion criteria, or outcome extraction; (2) the inclusion  
227 criteria was limited to larger trials; (3) the inclusion criteria was limited to higher  
228 methodological quality trial (Figure S5). An additional six outcomes, including growth,  
229 disability, and immune system disorders, were identified when in-depth interviews with  
230 women with lived experience of pre-eclampsia were thematically analysed.

231

#### 232 **Resource utilisation outcomes**

233 Considering the results of the systematic review, when no limitations were placed within the  
234 search strategy, inclusion criteria, or outcome extraction, four resource utilisation outcomes  
235 were identified (Figure S6). Limiting the search strategy did not reduce the number of  
236 resource utilisation outcomes identified. When commonly reported outcomes were extracted  
237 from trial reports, only two resource utilisation outcomes were identified. When primary  
238 outcomes were extracted from trial reports, no resource utilisation outcomes were identified.  
239 Thematic analysis of in-depth patient interviews identified three resource utilisation  
240 outcomes.

241

242

243

244

245

## 246 **Discussion**

### 247 **Main findings**

248 This study has demonstrated that different methodological decisions can make a substantial  
249 impact on the identification of potential core outcomes. Extracting outcomes from published  
250 pre-eclampsia trials was an effective way of identifying a range of maternal, fetal, and  
251 neonatal outcomes. However, limitations placed within the search strategy reduced the  
252 number and diversity of potential core outcomes identified, particularly for maternal and  
253 neonatal outcomes. Limiting the extraction of outcomes to primary outcomes or outcomes  
254 commonly reported in pre-eclampsia trials substantially reduced the number and diversity of  
255 potential core outcomes identified. Thematic analysis of in-depth interviews with women with  
256 lived experience of pre-eclampsia identified an additional 12 (10%) outcomes relating to their  
257 own wellbeing and the future health of their offspring. All outcomes will be entered into a  
258 Delphi survey to identify a core outcome set for pre-eclampsia.

259

### 260 **Strengths and limitations**

261 To our knowledge, this is the first study to objectively quantify the impacts of different  
262 methodological decisions on the identification of potential core outcomes. A diverse range of  
263 potential core outcomes, identified using quantitative and qualitative research, were  
264 successfully organised within a single taxonomy to ensure comparability. Descriptive tables  
265 were effective in demonstrating and quantifying the effect of different methodological  
266 decisions on the identification of potential core outcomes.

267

268 Our empirical evaluation has several limitations. Methodological decisions evaluated within  
269 this study were identified by reviewing core outcome set development studies relevant to  
270 women's health, applied to pre-eclampsia, and might be different in other topic areas.

271 Further research is required to explore other methodological decisions and to confirm the  
272 findings of this study are applicable in other core outcome set development studies

273 standardising outcomes in other disease areas such as infertility, endometriosis, and  
274 preterm birth.<sup>21-23</sup> The study did not evaluate the ease outcome collection, the quality of  
275 measurement of the outcome, or other relevant factors. Such an approach could have  
276 provided additional insight into the most appropriate methods to identify potential core  
277 outcomes. Future core outcome set developers should consider exploring these issues.

278

### 279 **Interpretation**

280 Previous core outcome set development studies have rarely discussed the impact of  
281 different methodological decisions on the development of a long list of potential core  
282 outcomes. An interim study published as part of the development of a core outcome set for  
283 preterm birth briefly discussed the potential impact of restricting the search strategy to  
284 recently published trials and only extracting primary outcomes from published preterm birth  
285 trials. The core outcome set developers noted the number and diversity of outcomes  
286 identified “*may have been influenced*” by these decisions.<sup>24</sup> The findings of this study  
287 confirms that careful attention should be paid to the development of a long list of potential  
288 core outcomes.

289

290 The need to develop core outcome sets in women’s health to address poorly chosen,  
291 collected, and reported outcomes has been demonstrated by several systematic reviews, in  
292 a diverse range of conditions including, endometriosis, twin-twin transfusion syndrome, and  
293 vaginal and pelvic organ prolapse.<sup>25-29</sup> Unfortunately, there is potential to waste limited  
294 resources and introduce unnecessary delays in identifying a useful core outcome sets if  
295 inappropriate development methods are used. There is currently limited guidance regarding  
296 the development of a long list of potential core outcomes and the following specific  
297 recommendations for future core outcome set developers are suggested.

298

299

300

301 **Recommendations for future core outcome set developers**

302 Both quantitative and qualitative research methods should be used in developing a long list  
303 of potential core outcomes. When undertaking a systematic review of published randomised  
304 trials to identify potential core outcomes, no limitations should be placed within the search  
305 strategy, inclusion criteria should be broad, and all outcomes should be extracted from trial  
306 reports. Restricting the extraction of outcomes from trial reports, including only extracting  
307 primary outcomes or commonly reported outcomes, is likely to decrease the number and  
308 diversity of potential core identified.

309

310 Thematic analysis of in-depth interviews with patients was an effective strategy to ensure  
311 relevance to a broad range of stakeholders. It should be noted that less resource intensive  
312 data collection methods, including focus groups, observation, and free text questionnaires,  
313 secondary analysis of existing data, or meta-synthesis, have not been formally evaluated  
314 and could be useful alternative to in-depth interviews. Using qualitative research methods is  
315 important as outcomes reported in published research may not hold the same relevance for  
316 patients, particularly when published trials pre-dates the recent emphasis on patient and  
317 public involvement in study design.

318

319 Future core outcome set developers should carefully consider and draw upon the expertise  
320 of a range of stakeholders when considering different methods to identify a robust set of  
321 potential core outcomes. The specific methods, justification for their selection, and their  
322 potential impact on the final core outcome set should be explicitly discussed within interim  
323 publications and the final core outcome set publication. This approach should increase  
324 transparency, improve clarity, and reduce bias.

325

326 Given the uncertainty in core outcome set development methods, further methodological  
327 research is required. A research agenda should be embedded within future core outcome  
328 set development studies to address this uncertainty and strengthen the evidence base.

329 Priority should be given to the evaluation of development methods which have the potential  
330 to minimise bias, maximise efficiency, and increase implementation. Further research is  
331 needed to understand the relationship between potential core outcomes entered into a  
332 consensus development method and the core outcomes eventually identified. Is a  
333 comprehensive long list of potential core outcomes required to secure a final core outcome  
334 set relevant to key stakeholders? The modified Delphi method is commonly used to identify  
335 consensus 'core' outcomes and enables participants to suggest additional outcomes to be  
336 entered into the consensus development process. What is not known is whether outcomes  
337 suggested by participants within the consensus development process could address  
338 perceived deficiencies in the methods used to develop a long list of potential core outcomes  
339 or even making certain methods redundant.

340

## 341 **Conclusion**

342 Different methodological decisions have considerable impact on the number and diversity of  
343 potential core outcomes identified. When designing a systematic review to identify potential  
344 core outcomes, future core outcome set developers should use an extensive search  
345 strategy, pursue a broad inclusion criterion, and extract all outcomes from published trial  
346 reports. Qualitative research has an important role in ensuring the long list of potential core  
347 outcomes holds sufficient relevance to patients. Future core outcome set developers should  
348 implement this study's recommendations to ensure comprehensive ascertainment of  
349 potential core outcomes.

350

## 351 **International Collaboration to Harmonise Outcomes in Pre-eclampsia (iHOPE)**

### 352 **Steering Group**

353 James M. N. Duffy (University of Oxford, Oxford, United Kingdom); Mark Brown (St George  
354 and Sutherland Hospitals, Kogarah, Australia); Chris Gale (Imperial College London,  
355 London, United Kingdom); William Grobman (Northwestern University, Chicago, United

356 States); Ray Fitzpatrick (University of Oxford, Oxford, United Kingdom); S. Ananth  
357 Karumanchi (Harvard Medical School, Boston, United States); Nuala Lucas (Obstetric  
358 Anaesthetists' Association, London, United Kingdom); Laura Magee (Kings College London,  
359 London, United Kingdom); Ben Mol (Monash University, Melbourne, Australia); Michael  
360 Stark (University of Adelaide, Adelaide, Australia); Shakila Thangaratinam (Queen Mary,  
361 University of London, London, United Kingdom); Mathew Wilson (University of Sheffield,  
362 Sheffield, United Kingdom); Janneke van 't Hooft (Academical Medical Centre, Amsterdam,  
363 Netherlands); Peter von Dadelszen (Kings College London, London, United Kingdom); Paula  
364 R. Williamson (University of Liverpool, Liverpool, United Kingdom); Khalid S. Khan (Queen  
365 Mary, University of London, London, United Kingdom); Sue Ziebland (University of Oxford,  
366 Oxford, United Kingdom); and Richard J. McManus (University of Oxford, Oxford, United  
367 Kingdom).

368

### 369 **Acknowledgements**

370 This report is independent research arising from a doctoral fellowship (DRF-2014-07-051)  
371 supported by the National Institute for Health Research. Prof. Richard McManus was  
372 supported by a National Institute for Health Research Professorship and receives support  
373 from the National Institute for Health Research Oxford Collaborations for Leadership in  
374 Applied Health Research and Care. Prof. Richard McManus and Prof. Sue Ziebland are  
375 supported by National Institute for Health Research Senior Investigator awards. The views  
376 expressed in this publication are those of the authors and not necessarily those of the  
377 National Health Service, the National Institute for Health Research, or the Department of  
378 Health.

379

380 We would like to thank the Radcliffe Women's Health Patient Participation group, Action on  
381 Pre-eclampsia, and our patient and public representatives who assisted with study design,  
382 data interpretation, and planned dissemination. We would like to thank colleagues at the  
383 Nuffield Department of Primary Care Health Sciences, University of Oxford including Jacqui

384 Belcher, Carla Betts, Lucy Curtin, Dawn Evans, Caroline Jordan, Sarah King, Sam  
385 Monaghan, Dan Richards-Doran, Nicola Small, Clare Wickings, and Elizabeth Wolliams for  
386 administrative, technical, and material support. We would like to thank colleagues at the  
387 Women's Health Research Unit, Queen Mary, University of London including Khalid Khan,  
388 Tracy Holtham and Rehan Khan for administrative, technical support, and subject specific  
389 expertise. We would like to thank David J. Mills for administrative and material support.

390

### 391 **Conflicts of interest**

392 Prof Richard J. McManus has received blood pressure monitors for research from Omron.  
393 The remaining authors no conflict of interests.

394

### 395 **Author contributions**

396 Study concept and design: JMD, SZ, and RMcM. Acquisition of data: JMD, MH, SZ, and  
397 RMcM. Analysis and interpretation of data: JMD, MH, SZ, and RMcM. Drafting of the  
398 manuscript: JMD, SZ, and RMcM. Critical revision of the manuscript for important intellectual  
399 content: MH. Obtaining funding: JMD, SZ, and RMcM. Study supervision: SZ, and RMcM.

400

### 401 **Sources of funding**

402 This report is independent research arising from a doctoral fellowship (DRF-2014-07-051)  
403 supported by the National Institute for Health Research. The National Institute for Health  
404 Research had no role in the study design, data collection and analysis, decision to publish,  
405 or preparation of the manuscript.

406

### 407 **Ethical approval**

408 Ethical approval was received from the National Research Ethics Service (reference  
409 number: 12/SC/0495) for the in-depth interviews with women with lived experience of pre-  
410 eclampsia.

411

412 **References**

- 413 1. Townsend R, Duffy JMN, Khalil A. Increasing value and reducing research waste in  
414 obstetrics: towards woman-centred research. *Ultrasound in Obstetrics & Gynecology*.0(ja).
- 415 2. Duffy JMN, Ziebland S, von Dadelszen P, McManus RJ. Tackling poorly selected,  
416 collected, and reported outcomes in obstetrics and gynecology research. *American Journal*  
417 *of Obstetrics & Gynecology*. 2019;220(1):71.e1-.e4.
- 418 3. Wilkinson J, Bhattacharya S, Duffy J, Kamath M, Marjoribanks J, Repping S, et al.  
419 Reproductive medicine: still more ART than science? *BJOG: An International Journal of*  
420 *Obstetrics & Gynaecology*. 2019;126(2):138-41.
- 421 4. Duffy J, Bhattacharya S, Herman M, Mol B, Vail A, Wilkinson J, et al. Reducing  
422 research waste in benign gynaecology and fertility research. *BJOG: An International Journal*  
423 *of Obstetrics & Gynaecology*. 2017;124(3):366-9.
- 424 5. Sileo FG, Duffy JMN, Townsend R, Khalil A. Addressing the variation in outcome  
425 reporting in high risk twin studies: The key to reducing research waste and improving clinical  
426 care. *Ultrasound in Obstetrics & Gynecology*.0(ja).
- 427 6. Duffy JMN, Rolph R, Gale C, Hirsch M, Khan KS, Ziebland S, et al. Core outcome  
428 sets in women's and newborn health: A systematic review. *BJOG: An International Journal*  
429 *of Obstetrics and Gynaecology*. 2017;124(10):1481-9.
- 430 7. Whitehouse KC, Kim CR, Ganatra B, Duffy JMN, Blum J, Brahmi D, et al.  
431 Standardizing abortion research outcomes (STAR): a protocol for developing, disseminating  
432 and implementing a core outcome set for medical and surgical abortion. *Contraception*.  
433 2017;95(5):437-41.
- 434 8. Khalil A, Duffy JMN, Perry H, Ganzevoort W, Reed K, Baschat AA, et al. Study  
435 protocol: developing, disseminating, and implementing a core outcome set for selective fetal  
436 growth restriction in monochorionic twin pregnancies. *Trials*. 2019 Jan 9;20(1):35.
- 437 9. Webbe J, Brunton G, Ali S, Duffy JM, Modi N, Gale C. Developing, implementing and  
438 disseminating a core outcome set for neonatal medicine. *BMJ Paediatrics Open*.  
439 2017;1(1):e000048.
- 440 10. Perry H, Duffy JMN, Reed K, Baschat A, Deprest J, Hecher K, et al. A core outcome  
441 set for the evaluation of treatments for twin-twin transfusion syndrome. *Ultrasound in*  
442 *Obstetrics & Gynecology*.0(ja).
- 443 11. Khalil A, Perry H, Duffy J, Reed K, Baschat A, Deprest J, et al. Twin–Twin  
444 Transfusion Syndrome: study protocol for developing, disseminating, and implementing a  
445 core outcome set. *Trials*. 2017 July 14;18(1):325.
- 446 12. Williamson PR, Altman DG, Bagley H, Barnes KL, Blazeby JM, Brookes ST, et al.  
447 The COMET Handbook: Version 1.0. *Trials*. 2017;18(S3):280.



- 448 13. Duffy J, McManus R. Influence of methodology upon the identification of potential  
449 core outcomes: recommendations for core outcome set developers are needed. *BJOG: An*  
450 *International Journal of Obstetrics & Gynaecology*. 2016;123(10):1599-.
- 451 14. Duffy JMN, van 't Hooft J, Gale C, Brown M, Grobman W, Fitzpatrick R, et al. A  
452 protocol for developing, disseminating, and implementing a core outcome set for pre-  
453 eclampsia. *Pregnancy Hypertension: An International Journal of Women's Cardiovascular*  
454 *Health*. 2016;6(4):274-8.
- 455 15. Duffy JMN, Hirsch M, Kawsar A, Gale C, Pealing L, Plana MN, et al. Outcome  
456 reporting across randomised controlled trials evaluating therapeutic interventions for pre-  
457 eclampsia. *BJOG: An International Journal of Obstetrics and Gynaecology*.  
458 2017;124(12):1829-39.
- 459 16. Duffy JMN, Hirsch M, Gale C, Pealing L, Kawsar A, Showell M, et al. A systematic  
460 review of primary outcome and outcome measure reporting in randomized trials evaluating  
461 treatments for preeclampsia. *International Journal of Gynecology and Obstetrics*.  
462 2017;139(3):262-7.
- 463 17. Duffy JMN, Thompson T, Hinton L, Salinas M, McManus RJ, Ziebland S. What  
464 outcomes should researchers select, collect, and report in pre-eclampsia research? A  
465 qualitative study exploring the views of women with lived experience of pre-eclampsia.  
466 *BJOG: An International Journal of Obstetrics and Gynaecology*. Submitted for publication: 14  
467 June 2018.
- 468 18. Duffy J, Hirsch M, Pealing L, Showell M, Khan K, Ziebland S, et al. Inadequate safety  
469 reporting in pre-eclampsia trials: a systematic evaluation. *BJOG: An International Journal of*  
470 *Obstetrics & Gynaecology*. 2018;125(7):795-803.
- 471 19. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.  
472 Assessing the quality of reports of randomized clinical trials: Is blinding necessary?  
473 *Controlled Clinical Trials*. 1996;17(1):1-12.
- 474 20. Kingsley C, Patel S. Patient-reported outcome measures and patient-reported  
475 experience measures. *BJA Education*. 2017;17(4):137-44.
- 476 21. Hirsch M, Duffy JMN, Barker C, Hummelshoj L, Johnson NP, Mol B, et al. Protocol  
477 for developing, disseminating and implementing a core outcome set for endometriosis. *BMJ*  
478 *Open*. 2016;6(12):e013998.
- 479 22. van 't Hooft J, Duffy JM, Daly M, Williamson PR, Meher S, Thom E, et al. A core  
480 outcome set for evaluation of interventions to prevent preterm birth. *Obstetrics and*  
481 *gynecology*. 2016;127(1):49-58.
- 482 23. Duffy JMN, Bhattacharya S, Curtis C, Evers JLH, Farquharson RG, Franik S, et al. A  
483 protocol developing, disseminating and implementing a core outcome set for infertility.  
484 *Human Reproduction Open*. 2018;2018(3).

- 485 24. Meher S, Alfirevic Z. Choice of primary outcomes in randomised trials and systematic  
486 reviews evaluating interventions for preterm birth prevention: a systematic review. *BJOG: An*  
487 *International Journal of Obstetrics & Gynaecology*. 2014;121(10):1188-94.
- 488 25. Hirsch M, Duffy JMN, Kuszniir JO, Davis CJ, Plana MN, Khan KS. Variation in  
489 outcome reporting in endometriosis trials: a systematic review. *American journal of obstetrics*  
490 *and gynecology*. 2016 Apr;214(4):452-64.
- 491 26. Perry H, Duffy JMN, Umadia O, Khalil A. Outcome reporting across randomized trials  
492 and observational studies evaluating treatments for twin-twin transfusion syndrome:  
493 systematic review. *Ultrasound in obstetrics & gynecology : the official journal of the*  
494 *International Society of Ultrasound in Obstetrics and Gynecology*. 2018 Nov;52(5):577-85.
- 495 27. Pergialiotis V, Durnea C, Elfituri A, Duffy J, Doumouchtsis S, International  
496 Collaboration for Harmonising Outcomes R, et al. Do we need a core outcome set for  
497 childbirth perineal trauma research? A systematic review of outcome reporting in  
498 randomised trials evaluating the management of childbirth trauma. *BJOG: An International*  
499 *Journal of Obstetrics & Gynaecology*. 2018;125(12):1522-31.
- 500 28. Durnea CM, Pergialiotis V, Duffy JMN, Bergstrom L, Elfituri A, Doumouchtsis SK, et  
501 al. A systematic review of outcome and outcome-measure reporting in randomised trials  
502 evaluating surgical interventions for anterior-compartment vaginal prolapse: a call to action  
503 to develop a core outcome set. *International Urogynecology Journal*. 2018 December  
504 01;29(12):1727-45.
- 505 29. de Mattos Lourenco TR, Pergialiotis V, Duffy JMN, Durnea C, Elfituri A, Haddad JM,  
506 et al. A systematic review on reporting outcomes and outcome measures in trials on  
507 synthetic mesh procedures for pelvic organ prolapse: Urgent action is needed to improve  
508 quality of research. *Neurourology and Urodynamics*. 2019;38(2):509-24.

509